Emerging pipeline drugs for hepatitis B infection

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728214.2011.646260PMID 22195605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE ENTRY INHIBITOR MYRCLUDEX-B EFFICIENTLY BLOCKS VIRAL SPREADING IN VIVO IN HUMAN LIVER CHIMERIC uPA/ SCID MICE PREVIOUSLY INFECTED WITH HEPATITIS B VIRUS

  2012cited by this paper
• A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

  2011cited by this paper
• 75 REP 9AC IS A POTENT HBSAG RELEASE INHIBITOR WHICH CLEARS SERUM HBSAG AND ELICITS SVRS IN PATIENTS WITH CHRONIC HEPATITIS B

  2011cited by this paper
• Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study

  2011cited by this paper
• Lessons from maraviroc clinical trials

  2011cited by this paper
• Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B.

  2011cited by this paper
• Peginterferon plus adefovir versus either drug alone for hepatitis delta.

  2011cited by this paper
• Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication.

  2011cited by this paper
• Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta

  2011influential reference
• 100 THERAPEUTIC EFFICACY OF THE TLR7 AGONIST GS-9620 FOR HBV CHRONIC INFECTION IN CHIMPANZEES

  2011cited by this paper
• Hepatitis delta virus.

  2011cited by this paper
• 1353 A PHASE IIB STUDY OF THE EFFICACY AND SAFETY OF LB80380 VS ENTECAVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS B

  2011cited by this paper
• 1114 ANTI-VIRAL EFFICACY AND INDUCTION OF AN ANTIBODY RESPONSE AGAINST SURFACE ANTIGEN WITH THE TLR7 AGONIST GS-9620 IN THE WOODCHUCK MODEL OF CHRONIC HBV INFECTION

  2011cited by this paper
• Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysis

  2011cited by this paper
• Antiviral activity and safety of LB80380 in hepatitis B e antigen–positive chronic hepatitis B patients with lamivudine‐resistant disease

  2010cited by this paper
• Solid-Phase Synthesis of the Lipopeptide Myr-HBVpreS/2-78, a Hepatitis B Virus Entry Inhibitor

  2010cited by this paper
• Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.

  2010cited by this paper
• Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus

  2010cited by this paper
• Effect of conventional interferon‐α in patients with HBeAg‐positive chronic hepatitis B: a systematic review and meta‐analysis

  2010cited by this paper
• Chronic hepatitis B : an update

  2010cited by this paper
• Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy

  2010cited by this paper
• Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment

  2010cited by this paper
• Treatment with peginterferon versus interferon in Chinese patients with hepatitis B.

  2010cited by this paper
• Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study

  2010cited by this paper
• Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

  2010cited by this paper
• Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B.

  2010cited by this paper
• Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels

  2010cited by this paper
• Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients

  2009cited by this paper
• EASL Clinical Practice Guidelines: management of chronic hepatitis B.

  2009cited by this paper
• Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

  2009cited by this paper
• Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

  2009cited by this paper
• Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

  2009influential reference
• Endpoints of therapy in chronic hepatitis B

  2009cited by this paper
• Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients.

  2009influential reference
• Chronic hepatitis B: Update 2009

  2009cited by this paper
• Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

  2009cited by this paper
• A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B

  2009cited by this paper
• 907 INCREASED RISK WITH COMBINATION OF TELBIVUDINE AND PEGYLATED-INTERFERON ALFA-2A IN STUDY CLDT600A2406, COMPARED TO UNCOMMON RATE WITH TELBIVUDINE MONOTHERAPY FROM THE NOVARTIS GLOBAL DATABASE

  2009cited by this paper
• Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B

  2009cited by this paper
• Monotherapy versus combination therapy for the treatment of chronic hepatitis B

  2009cited by this paper
• Control of cccDNA function in hepatitis B virus infection.

  2009cited by this paper
• Profound Antiviral Effect of Oral Administration of MIV-210 on Chronic Hepadnaviral Infection in a Woodchuck Model of Hepatitis B

  2009cited by this paper
• Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.

  2009cited by this paper
• Telbivudine versus lamivudine in patients with chronic hepatitis B.

  2008cited by this paper
• A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels

  2008cited by this paper
• Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.

  2008cited by this paper
• Combination therapy of thymosin alpha‐1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study

  2008cited by this paper
• Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein

  2008cited by this paper
• Hepatitis B virus infection.

  2008cited by this paper
• Inhibition of Hepatitis B Virus Replication by Bay 41-4109 and Its Association with Nucleocapsid Disassembly

  2008cited by this paper
• Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.

  2008cited by this paper
• Preclinical development of the amphipathic DNA polymer REP 9AC for the treatment of hepatitis B virus Infection

  2008cited by this paper
• Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus

  2007influential reference
• Twenty‐four‐week clevudine therapy showed potent and sustained antiviral activity in HBeAg‐positive chronic hepatitis B

  2007cited by this paper
• Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist

  2007cited by this paper
• Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

  2007cited by this paper
• Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

  2007cited by this paper
• Effect of Lowering HBV DNA Levels by Initial Antiviral Therapy Before Adding Immunomodulator on Treatment of Chronic Hepatitis B

  2007cited by this paper
• Telbivudine versus lamivudine in patients with chronic hepatitis B.

  2007cited by this paper
• Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers

  2007cited by this paper
• Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

  2006cited by this paper
• Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

  2006cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• Hepatitis Delta Virus

  2006cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

  2006cited by this paper
• Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.

  2006cited by this paper
• A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B

  2006cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• BAY 41‐4109 has multiple effects on Hepatitis B virus capsid assembly

  2006cited by this paper
• A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.

  2005cited by this paper
• Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial

  2005cited by this paper
• Hepatitis B

  2005cited by this paper
• Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

  2005cited by this paper
• A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

  2005cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir

  2005cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004cited by this paper
• Evolving strategies to prevent HBV recurrence

  2004cited by this paper
• Epidemiology of hepatitis B in Europe and worldwide.

  2003influential reference
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

  2003cited by this paper
• Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

  2003cited by this paper
• Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

  2003cited by this paper
• Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses

  2002cited by this paper
• Fanconi syndrome and renal failure induced by tenofovir: a first case report.

  2002cited by this paper
• Hepatitis B e antigen and the risk of hepatocellular carcinoma.

  2002cited by this paper
• Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

  2001cited by this paper
• Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  2000cited by this paper
• Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy.

  2000cited by this paper
• Lamivudine as initial treatment for chronic hepatitis B in the United States.

  1999cited by this paper
• A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly.

  1997cited by this paper
• Hepatitis B virus infection.

  1997cited by this paper
• Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.

  1996cited by this paper
• Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study.

  1993influential reference
• Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial.

  1987cited by this paper
• Two distinct types of hepatitis in experimental hepatitis B virus infection.

  1980cited by this paper
• Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN –

  year unknowncited by this paper

• Efficacy and in vitro pharmacological assessment of novel N-hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors

  2024cites this paper
• Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus.

  2023cites this paper
• Ageing and non-liver comorbidities in population with chronic hepatitis B infection in the western pacific region from 1990 to 2019

  2023cites this paper
• In vitro evaluation of tropolone absorption, metabolism, and clearance.

  2023cites this paper
• Uracil derivatives as non-nucleoside inhibitors of viral infections

  2021cites this paper
• The hepatitis B virus polymerase.

  2021cites this paper
• Inhibition of HBV replication by N‐hydroxyisoquinolinedione and N‐hydroxypyridinedione ribonuclease H inhibitors

  2019cites this paper
• Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B

  2019cites this paper
• Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores.

  2018cites this paper
• Discovery of Small Molecule Therapeutics for Treatment of Chronic HBV Infection.

  2018cites this paper
• Inhibition of hepatitis B virus replication by N‐hydroxyisoquinolinediones and related polyoxygenated heterocycles

  2017cites this paper
• 3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H

  2017cites this paper
• Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations

  2016cites this paper
• Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors.

  2016cites this paper
• Referral of newly diagnosed chronic hepatitis B and C patients in six EU countries: results of the HEPscreen Project.

  2016cites this paper
• Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors.

  2016cites this paper
• The hepatitis B virus ribonuclease H as a drug target.

  2015cites this paper
• Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure

  2015cites this paper
• Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation

  2014cites this paper
• Epidemiology and Clinical Features of Childhood Chronic Hepatitis B Infection Diagnosed in England

  2014cites this paper
• Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method

  2013cites this paper
• Paediatrics: Children need optimal management of chronic hepatitis B

  2013cites this paper
• β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity.

  2013cites this paper
• A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B

  2013cites this paper
• Chapter Seventeen – Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection

  2013cites this paper
• The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes

  2013cites this paper